The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP FIGI (to the nearest dollar) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
AMBRX BIOPHARMA INC SPONSORED ADS 02290A102   100,836,791 11,304,573 SH   SOLE   11,304,573 0 0
ARGENX SE SPONSORED ADR 04016X101   106,259,071 285,198 SH   SOLE   285,198 0 0
KEROS THERAPEUTICS INC COM 492327101   1,340,182 31,386 SH   SOLE   31,386 0 0
TG THERAPEUTICS INC COM 88322Q108   157,186,665 10,451,241 SH   SOLE   10,451,241 0 0